investment software

1. Roses are red, markets are too: There’s a fair bit of red in the stock markets right now, but losses aren’t so steep that they’ll break your heart.

U.S. stock futures are flat.

Most Asian markets closed in negative territory. Stocks are mixed in Europe.

The lackluster action comes after U.S. stocks hit fresh record highs on Monday.

The Dow Jones industrial average and S&P 500 have both rallied by between 3% to 4% since the start of the year. The Nasdaq is up a whopping 7%.

Shares in iPhone maker Apple (AAPL, Tech30) are trading near their highest level ever.

2. Janet Yellen in the hot seat: Federal Reserve chief Janet Yellen is giving semi-annual testimony to the U.S. Senate at 10 a.m. ET.

The Fed is considered the driving force behind the multi-year bull market rally in stocks since the Great Recession.

What Yellen says about the timing and magnitude of future interest rate hikes could keep the rally going full steam ahead — or stop it dead in its tracks.

investment software: U.S. Bancorp(USB)

Advisors’ Opinion:

  • [By John Maxfield]

    One of this era’s most successful bankers has decided to relinquish the reins. U.S. Bancorp (NYSE:USB) announced on Tuesday that chairman and CEO Richard Davis will step down from his role as CEO at the bank’s annual meeting in April. He’ll stay on as executive chairman of the board, while President and COO Andy Cecere will succeed him in the corner office.

  • [By Sarfaraz Khan]

    In addition to this, Warren Buffett has also built sizable positions in a number of major US banks.Wells Fargo (NYSE:WFC), U.S. Bancorp (NYSE:USB)and Goldman Sachs (NYSE:GS)have the leading positions in Berkshire Hathaways portfolio. In fact, Wells Fargo is Berkshire Hathaway’s second largest stock holding. In addition to this, Berkshire Hathaway also owns $5 billion worth of Bank of Americas preferred shares and warrants to buy 700 million of the banks ordinary shares at just $7.14 (current price $22.10) anytime until September 2021. These banks are positioned to become the biggest beneficiaries of the increase in interest rates. To get an idea of how this might happen, consider Bank of Americas forecast in which it predicted a $7.5 billion boost to annual net interest income following a 1-percentage-point increase in interest rates.

investment software: Coca-Cola Company (The)(KO)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By Paul Ausick]

    The Coca-Cola Co. (NYSE: KO) traded down 1.91% at $45.66. The stock’s 52-week range is $39.88 to $47.48. Volume was about 50% higher than the daily average of around 9.2 million shares. The company had no specific news Friday.

  • [By Douglas A. McIntyre]

    Coke’s old CEO is out, and another Coca-Cola Co. (NYSE: KO) executive is in. That probably has little to do with Coke’s major problems, which will not be easy to solve. The first is a relentless drum beat from health experts about the dangers of sugar. As obesity and diabetes grow across most of the developed world, the old snacks are being replaced by healthier foods. In the emerging markets, slowing economies may undermine consumer spending. Coke has few large markets where it can turn to for growth.

  • [By Money Morning Staff Reports]

    Represented are Wells Fargo & Co. (NYSE: WFC), Coca-Cola Co. (NYSE: KO), and Kraft Heinz Co. (Nasdaq: KHC), just to name a few.

    The Berkshire portfolio has 34 dividend stocks in total; of those, eight yield dividend returns in excess of 3% annually, according to Buffett’s latest SEC 13F filing on Feb. 14, 2017.

investment software: Vuzix Corporation(VUZI)

Advisors’ Opinion:

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By William Patalon III]

    Vuzix Corp. (Nasdaq: VUZI) – the “augmented reality” company whose shares more than doubled following our September 2015 recommendation – said that its new “smart glasses” were just honored with a “Wearable Device of the Year” award.

investment software: Washington Trust Bancorp, Inc.(WASH)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

best online stock trading

Homeowners often have to deal with a flurry of costs associated with buying or maintaining a house. There are some costs and expenses that most can understand and predict when it comes to homeownership. However, there are some that can sneak up on first-time buyers, and here take a look at a few of those. 24/7 has also listed the top 10 markets that have the highest hidden costs associated with owning a home.

Property taxes ranked as perhaps the biggest home expense that people see after having a mortgage. Long-time homeowners may have gotten used to this, but those new to the game might be surprised at how much these taxes can run.

Home insurance makes the list as another top hidden cost associated with homeownership. For those that have taken out a mortgage, the lender requires the purchase of this insurance. Although this insurance may not do a lot for most, it is invaluable for some that lose everything in a flood or natural disaster.

Maintenance and remodeling are also major expenses to consider when owning a home. Some buy a home just to fix it up and then flip it for some extra cash. However, without experience in this field, remodeling could be a costly affair. According to the Joint Center for Housing Studies at Harvard, American homeowners spent $361 billion on home improvements. Thats up 13.5% from the previous peak in 2007.

best online stock trading: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Tom Gentile]

    After the Senate scored the votes on Tuesday to review a plan for repealing or repealing and replacing what’s come to be known as Obamacare, we saw a mixed-bag reaction from healthcare stocks. Even some of the bulletproof ones, like Amgen Inc. (Nasdaq: AMGN), closed lower from their opening highs.

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Johanna Bennett]

    Shares of Amgen (AMGN) led the drop in the S&P 500 today falling almost 6.4% to close at $168.61 after the drug maker unveiledlong-awaited data on its anti-cholesterol drug Repatha.

    Can shares of Amgen rebound from todays selloff?

    Yes, is the answer from RBC Capital Management analyst Michael Yee. He argues that the drug makers share price can grind back up if access to Repatha increases over the next few quarters. Earlier today, Amgen released data from an outcome study that missed expectations, leading some analyst to predict that health plans will continue to restrict access to the drug.

    As Yee writes:

    A number of key developments midday at the ACC conference that should shed increased confidence that Repatha reimbursement and utilization will continue to increase over time driving a new growth driver for AMGN and increased confidence in a new product cycle. If reimbursement does start to open up over next few quarters (tracking IMS scripts and other datapoints) and AMGN manages their execution on quarters/guidance – stock should recover off today’s overreaction reflecting high expectations

best online stock trading: CytomX Therapeutics, Inc.(CTMX)

Advisors’ Opinion:

  • [By Lisa Levin]

    CytomX Therapeutics Inc (NASDAQ: CTMX) shares were also up, gaining 24 percent to $18.89. Bristol-Myers Squibb Co (NYSE: BMY) and CytomX Therapeutics disclosed that they have extended worldwide partnership to discover Probody therapeutics for the treatment of cancer and other diseases.

best online stock trading: Gold Standard Ventures Corporation(GSV)

Advisors’ Opinion:

  • [By Sara Cornell]

    The management team member who garners the most attention right now is Dave Mathewson, VP, Head of Exploration. Dave is a geologist with more than 35 years’ experience in the gold exploration space, and specifically, in Nevada. He is credited with a number of notable discoveries for Newmont Mining Corp (NYSE: NEM), and later went on to Gold Standard Ventures Corp (NYSE: GSV) helping take that company from a start-up to a now $481 million market cap.

best online stock trading: HCI Group, Inc.(HCI)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Florida insurance stock HCI Group Inc (NYSE: HCI) has taken a hit with shares down around 21% over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 2.74%on Friday when it became clear that it would not be as catastrophic as feared:

Stamps.Com: Where Growth And Value Meet

Stamps.com (NASDAQ: STMP) is a leading provider of online postage and shipping solutions and operates primarily in the United States. The software-based company consists of five major brands including Stamps.com, Encidia, Shipworks, Shipstation, and Shipping Easy. Stamps.com was founded in 1996 and began trading on the Nasdaq exchange in 1999 but was relatively unknown in the investing world until the last three years. Even today its trading volume is just over 400,000 and unless you use their products, own shares, or own shares of a competitor, it is likely you don’t know much about the company. In this article, I will explain my thesis as to why this is a company that is worth putting on your investing radar.

Ecommerce is growing by leaps and bounds.

In the interest of full disclosure, I will start by pointing out that I have had a vested interest in Stamps.com for some time. I owned the stock for about a year back in 2012 and sold for a very small gain and have kept tabs on it ever since. About a year ago, I initiated a new position and have since added to the position to the point where it is now my second largest holding, representing 12% my personal portfolio.

Opinions on Stamps.com vary wildly, and that variance can be seen in its stock price action over the past couple of years. The chart below shows the outsized gains and losses stockholders have endured in the last couple of years, at least on paper. With significant skin in the game, I believe it is prudent to vet all the opinions, both bullish and bearish to determine which opinions carry the most weight and determine a strategy going forward. In the balance of the article, I will examine the most prevalent reasons for the recent pullback and explain why I am convinced Stamps.com provides an excellent combination of growth and value for your portfolio.

Chart
STMP data by YCharts

The fall from grace

On November 2nd, STMP opened at $226.45 and reported what appeared to be blowout earnings after the bell. The company reported earnings of $2.68 per share, trouncing estimates of $1.95 per share. On a GAAP basis, earnings were $2.49 per share. Total revenue and EBITDA were both up 24% YOY (year over year).

Despite the strong beat on both revenue and earnings, the bears came out of hibernation after the close. Interestingly, the stock started dropping even before earnings results were released. By the time the market closed on November 3rd, STMP was trading at $171.10 per share, representing a 24% drop in just two days. Before we get into potential catalysts for the stock going forward, let’s examine the main arguments given for the sell-off and decide how much they should affect our investing thesis going forward.

1. Competitive threats

The company’s main competitors include UPS (NYSE: UPS), FedEx (NYSE: FDX), Pitney Bowes (NYSE: PBI), Amazon (NASDAQ: AMZN), and Etsy (NASDAQ:ETSY). Clearly, Amazon and Pitney Bowes are the two competitors that have investors most concerned. Pitney Bowes unveiled a low-cost offering in June with the intent of taking market share and Amazon recently announced a new offering called Seller Flex.

Now, competition matters and the management team at Stamps.com takes it seriously. At the same time, I’m not ready to overreact to recent moves by either competitor. Pitney Bowes’ latest move was to acquire a warehouse company with 1.2 million square feet of warehouse space. That is not even a part of Stamps.com’s business. As far as Amazon is concerned, anytime Amazon is mentioned as a competitor, investor fears go into overdrive. An interesting thing about Stamps.com’s business is that their main competitors in some aspects of their business are partners in other aspects. Stamp.com CEO Ken McBride stated that he actually sees Seller Flex as an enhancement to his company’s solutions.

2. Slowing growth

A case could be made that revenue growth is slowing. In Q2, Stamps.com revenues showed a 38% uptick over the same period on 2016. In Q3, sales growth slowed to 24%. While there is no denying 24 is less than 38, there is also no denying the fact that 24% growth is a pretty robust number. According to Yahoo Finance, the five analysts following the stock expect earnings to grow by 15% over the next five years. That is a number most companies would love to have.

3. Insider sales

In early November, Barron’s penned an article highlighting an unusually high volume of insider sales. The author implied these were deceptive trades and referred to them as “back of the envelope” calculations. Certainly, that was worth checking into.

The first thing I learned while researching the matter was there was nothing sneaky involved. In fact, it took me about 30 seconds to find all the insider trading activity on the company’s website. A closer look at SEC documents revealed the fact that several executives did indeed sell stock but they simultaneously exercised options for an equal number of shares. Since most options were exercised for well under $100, the simultaneous move of exercising options and selling stock made sense to me. By liquidating a significant amount of money they can use in their daily lives and turning options into and an equal number of shares, the executives were able to have their cake and eat it too.

The insinuation with any article highlighting insider sales is that executives think their company’s stock is fully valued, or even overpriced. That simply is not true. Google’s founding executives exercised plenty of options as the company matured. Howard Schultz sold plenty of Starbucks stock, even as the company was growing. While there is no way of knowing for sure, it seems that in the case of Stamps.com, the company does not believe its stock is overvalued. My main evidence for this statement is the fact that the company repurchased $103 million worth of stock and paid out $33 million in stock compensation. Those are hardly the actions of a management team who believes its stock price will decline.

4. Tax credit

As noted earlier, the company reported Q3 results that, on the surface, blew away expectations. The company’s revenue was up 24% YOY and earnings per share were up 73%. Naysayers will point to the $11 million tax credit which inflated earnings numbers and to a point they are correct. Both the tax credit and changing tax rates inflated EPS numbers and made YOY comparisons a little cloudier. However, investors who want to avoid the confusion that comes with these tax items do have other numbers to look at. Specifically, investors can see that revenues rose by 24%, gross margin was up about 1%, EBITDA rose by 24%, and income before taxes rose by 13%. All of these numbers negate the effect of the tax credit and represent solid financial performance.

5. High short interest

This is a non-issue. Short interest does not necessarily have anything to do with the underlying fundamentals of a company.

6. A personal concern

Stamps.com does pay out a very high percentage of its net income in stock-based compensation. In theory, I like stock-based compensation because it ensures that the company’s interests are aligned with those of its shareholders. However, with Stamps.com, the amount of stock-based compensation is a little higher than I would like. The table below shows the amount of stock-based compensation paid over the last three quarters by Stamps.com and one of its largest competitors.

Company Net Income Stock-Based Compensation % of Net Income
Stamps.com $110,403,000 $33,669,000 30.5%
Pitney Bowes $171,392,000 $18,312,000 10.7%

SOURCE: SEC FILINGS FOR STAMPS.COM AND PITNEY BOWES

Why Stamps.com is likely to rebound

The growth story continues

In September, Forbes Magazine named Stamps.com to its list of 25 Fastest Growing Public Tech Companies. The chart below shows that the company has rewarded shareholders to the tune of 276% in the past three years and justified that uptick with a corresponding jump in both revenues and net income. In addition to the metrics shown in the chart, paying customers and average revenue per user are both coming in at an all-time high. The five analysts that follow the company continue to expect significant growth going forward with a five-year annual growth projection of 15%.

Chart
STMP data by YCharts

The value proposition

One would think that with a stock price rising almost 300% in three years, the stock’s valuation would become a little rich and ripe for a pullback. In actuality, the chart above shows that earnings growth has slightly outpaced the stock price. The valuation has stayed in check.

Further, I’d like to point out that most major financial websites overstate the company’s PE ratio. Yahoo Finance shows STMP as having a PE of 28.12 and FactSet shows a PE of 22.91. If you take the midpoint of those two numbers, you get a PE of 25, right in line with that of the S&P 500. If you do your own math, however, you will find that STMP has an even lower valuation than reported by these sites.

As we look at the last four quarter sequentially, we see EPS numbers of $2.73, $1.83, $2.08 and $2.68. Adding them up gives us a trailing 12 months EPS of $9.32. Using Monday’s opening stock price of $175, that gives us a trailing 12 month PE of 17.78. That is a surprisingly low valuation for a company expected to grow earnings at 15% annually for the next five years.

Looking ahead

As investors, especially long-term investors, we are much more interested in where a stock is going than where it is right now. With that in mind, I will make a conservative projection based on analysts’ predicted growth rates. Since Stamps.com has handily beaten estimates in each of the last five quarters, I would expect them to at least meet expectations in the next four quarters so I will apply the consensus 15% growth rate to the first year. After that, I will model for 14% growth in years two and three and 12% growth in years four and five. Then, I will apply a PE of 21 for the year 2022 and we will see where we land. The yearly calculations are below:

Year EPS Growth Earnings Per Share Stock Price
2018 15% $10.72 $225
2019 14% $12.22 $256
2020 14% $13.93 $293
2021 12% $15.60 $327
2022 12% $17.42 $367

DATA SOURCE: STAMPS.COM AND YAHOO FINANCE

Final take

Stamps.com seems to be in exactly the right place at exactly the right time. Stamps.com is a rapidly growing company and a fast-growing industry that is showing no signs of slowing down. While I could nitpick and find a couple flaws, like their overgenerous stock-based compensation formula, all in all, things look promising going forward. As the only pureplay in software postage and shipping solutions, I believe Stamps.com will continue to reap the benefits of the growth in e-commerce and as an investor, the potential rewards far outweigh any risks.

Disclosure: I am/we are long STMP.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.Tagged: Investing Ideas, Long Ideas, Services, Catalog & Mail Order HousesWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here

Best Warren Buffett Stocks To Buy For 2018

In his annual shareholder letter, JPMorgan CEO Jamie Dimon pointed to data showing a radically shrinking U.S. stock market, echoing an increasingly common refrain on Wall Street and in corporate America. Dimon is working alongside business luminaries such as Warren Buffett, BlackRock’s Larry Fink and GM CEO Mary Barra to promote long-term stock market investment and regulations that will make it easier and more rewarding for companies to sell their shares on public markets.

On Wednesday morning, the U.S. markets lost another stock when European consumer products conglomerate JAB Holding agreed to buy Panera Bread for $7.5 billion, ending the popular soup, sandwich and salad chain’s stellar over-quarter century run on public markets. There are many causes of the shrinking stock market, for instance the administrative costs of being publicly traded and strict regulations surrounding investor communications, but JAB’s emergence and its deal for Panera Bread points to the biggest culprit.

Best Warren Buffett Stocks To Buy For 2018: Atlantic Power Corporation(AT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and Pampa Energia S.A. (ADR) (NYSE: PAM), down 4 percent.

  • [By Lisa Levin] Related WR Earnings Scheduled For February 24, 2016 Mid-Day Market Update: Ocata Therapeutics Climbs On Acquisition News; Textura Shares Slip
    Related AT Mid-Morning Market Update: Markets Open Higher; Tiffany Misses Q2 Expectations PVH Corp, Atlantic Power, Carlyle Group Lead Monday's After-Hours Movers Atlantic Power's (AT) CEO Jim Moore on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    Toward the end of trading Thursday, the Dow traded down 0.24 percent to 16,960.40 while the NASDAQ declined 0.38 percent to 4,656.49. The S&P also fell, dropping 0.17 percent to 1,985.91.

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and SCANA Corporation (NYSE: SCG) down 1 percent.

Best Warren Buffett Stocks To Buy For 2018: FMC Technologies, Inc.(FTI)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Following a series of M&A announcements in the oilfield-services sector since the onset of the oil market downturn, French oil-field service company Technip and U.S. oilfield equipment company FMC Technologies (NYSE:FTI) hooked up in an all-stock deal valuing the combined company at $13 billion. Shareholders of each company will own 50% of the combined entity, to be named TechnipFMC, which implies a roughly $6.5 billion acquisition valuation for each entity. The transaction, which should close early next year, will “combine Technip’s innovative systems and solutions, state-of-the-art assets, engineering strengths, and project management capabilities with FMC Technologies’ leading technology, manufacturing, and service capabilities.” Further, it should save $400 million in annual costs by 2019. Moreover, it will enable the combined company to compete better against larger oil-field service rivals Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), and Schlumberger (NYSE:SLB), which have all gained strength during the downturn either through M&A activities or cost savings initiatives.

Best Warren Buffett Stocks To Buy For 2018: Glu Mobile Inc.(GLUU)

Advisors’ Opinion:

  • [By Harsh Chauhan]

    Mobile gaming specialist Glu Mobile’s (NASDAQ:GLUU) net loss almost tripled in the first quarter despite a slight jump in revenue from the prior-year period. Its adjusted net loss of $0.15 per share was more than twice than Wall Street’s expectations of a $0.07-per-share loss.

  • [By Jim Robertson]

    The gaming space has a reputation for beingdominated by male gamers and full of big-budget combat and action orientated games geared for men. However, thats not necessarily the case. Last December, Glu Mobile Inc (NASDAQ: GLUU)bought CrowdStarfor $45 million acquiring a game publisher that has had rare success with female gamers throughitsCovet Fashionwhile its last independently produced title, Design Home, has also proved to be another hit with women (about 90% ofDesign Homesplayers are female who are a little older than the Covet Fashion audience).

  • [By Peter Graham]

    A long term performance chart shows that Zynga Inc peaked after the IPO, but has at least been less volatile since then compared to the performance of remaining small cap mobile gaming stockGlu Mobile Inc (NASDAQ: GLUU) and large capActivision Blizzard:

Best Warren Buffett Stocks To Buy For 2018: LATAM Airlines Group S.A.(LFL)

Advisors’ Opinion:

  • [By Monica Gerson]

    LATAM Airlines Group SA (ADR) (NYSE: LFL) is projected to post its quarterly earnings at $0.08 per share on revenue of $2.40 billion.

    Weibo Corp (ADR) (NASDAQ: WB) is expected to post its quarterly earnings at $0.04 per share on revenue of $113.66 million.

Top Performing Stocks To Watch Right Now

Health savings accounts are poised for a major expansion by Republicans in Washington, D.C., and that could mean millions more customers and fees flowing to a handful of companies.

Investors are betting on it, bidding up shares of HSA provider HealthEquity (HQY) by about 35% since the November election. It’s one of the best performing stocks on Wall Street since Donald Trump won the White House.

Another big beneficiary might be Optum Bank, the industry leader, with more than 3 million of these accounts and about $7 billion in assets it manages for consumers. It’s owned by the nation’s largest health insurer, UnitedHealth Group.

For years, these companies and others have been lobbying lawmakers for changes that could become reality with a Republican-controlled Congress and Trump administration.

The GOP health law replacement plan introduced Monday in the House reflects the party’s broad consensus for giving more Americans access to HSAs, which allow people to put aside money tax-free for medical expenses.

Top Performing Stocks To Watch Right Now: MGM Resorts International(MGM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Avon Products, Inc. (NYSE: AVP) to report quarterly earnings at $0.10 per share on revenue of $1.62 billion before the opening bell. Avon Products shares rose 2.39 percent to $6.00 in after-hours trading.
    Analysts expect MGM Resorts International (NYSE: MGM) to report quarterly earnings at $0.20 per share on revenue of $2.44 billion before the opening bell. MGM shares rose 1.01 percent to $29.90 in after-hours trading.
    Cisco Systems, Inc. (NASDAQ: CSCO) reported better-than-expected results for its second quarter and raised its quarterly dividend to $0.29 per share. Cisco shares rose 2.13 percent to $33.52 in the after-hours trading session.
    Before the markets open, Dean Foods Co (NYSE: DF) is projected to report its quarterly earnings at $0.41 per share on revenue of $2.01 billion. Dean Foods shares rose 0.49 percent to $20.55 in after-hours trading.
    Tripadvisor Inc (NASDAQ: TRIP) posted weaker-than-expected results for its fourth quarter on Wednesday. Tripadvisor shares dropped 5.60 percent to $49.75 in the after-hours trading session.
    Analysts are expecting Waste Management, Inc. (NYSE: WM) to have earned $0.77 per share on revenue of $3.42 billion in the latest quarter. Waste Management will release earnings before the markets open. Waste Management shares rose 2.27 percent to $72.97 in after-hours trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Wayne Duggan]

    According to Deutsche Bank analyst Carlo Santarelli, news that Las Vegas Sands Corp. (NYSE: LVS) may be selling its Sands Bethlehem resort to MGM Resorts International (NYSE: MGM) could be a win-win-win for Sands, MGM and MGM Growth Properties LLC (NYSE: MGP).

  • [By Wayne Duggan]

    Bernstein maintains Outperform ratings on Melco Crown Entertainment Ltd (ADR) (NASDAQ: MPEL) and the China units of Wynn Resorts, Limited (NASDAQ: WYNN) and MGM Resorts International (NYSE: MGM).

  • [By Jon C. Ogg]

    MGM Resorts International (NYSE: MGM) is also a top pick for the first quarter, and Merrill Lynch’s price objective of $33.00 was versus a recent price of $28.50. The consensus analyst target price is a tad higher at $33.86.

  • [By Ben Levisohn]

    Wynn wasn’t the only Macau casino operator that took it on the chin today. Las Vegas Sands (LVS) tumbled 13% to $54.67, while Melco Crown Entertainment (MPEL) plunged 14% to $16.87, and MGM Resorts International (MGM) dropped 4.3% to $28.65.

Top Performing Stocks To Watch Right Now: Blue Buffalo Pet Products, Inc.(BUFF)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q3 2016 earnings report formid cap pet stock Blue Buffalo Pet Products Inc (NASDAQ: BUFF)is scheduled for after the market closes onThursday (November 10th) with earnings beating expectations the last time around.

  • [By Peter Graham]

    A long term performance chart shows shares of Petmed Express giving a steady performance before jolting higher this yearand pet stock peerCentral Garden & Pet Co (NASDAQ: CENT) also being agood performer while pet food stocks Blue Buffalo Pet Products Inc (NASDAQ: BUFF) and Freshpet Inc (NASDAQ: FRPT) have not yet lived up to investor expectations:

  • [By Monica Gerson] Related BUFF Mid-Afternoon Market Update: Crude Oil Rises 3.5%; Zagg Shares Fall Following Weak Q4 Results Mid-Day Market Update: Blue Buffalo Pet Products Rises Following Strong Q4 Results; Ocean Rig UDW Shares Slide Blue Buffalo Pet Products' (BUFF) CEO Kurt Schmidt on Q1 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related ARMK Earnings Scheduled For May 11, 2016 Earnings Scheduled For February 10, 2016

    Some of the stocks that may grab investor focus today are:

  • [By Peter Graham]

    Mid cap pet stock Blue Buffalo Pet Products Inc (NASDAQ: BUFF)reportedQ1 2017 earnings after the market closed Tuesday.Net sales increased 7.9% to $302.0 million driven primarily by volume growth. Net sales of Dry Foods increased 6.4% to $245.2 million while net sales of Wet Foods, Treats and Other Products increased15.1% to $56.8 million. Net income increased 18.1% to $44.1 million and cash and cash equivalents were $338.2 million as of March31, 2017 versus $292.7 million as of December31, 2016. The CEO commented:

Top Performing Stocks To Watch Right Now: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

Top Performing Stocks To Watch Right Now: Nord Anglia Education, Inc.(NORD)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggested going long on small cap international school stock Nord Anglia Education Inc (NYSE: NORD):

  • [By Lisa Levin]

    Nord Anglia Education Inc (NASDAQ: NORD) shares shot up 19 percent to $32.83 after the company agreed to be acquired for $32.50 per share in cash.

Top Performing Stocks To Watch Right Now: SVB Financial Group(SIVB)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, financial shares slipped by 0.55 percent. Meanwhile, top losers in the sector included Greenhill & Co., Inc. (NYSE: GHL), down 11 percent, and SVB Financial Group (NASDAQ: SIVB), down 8 percent.

  • [By Jon C. Ogg]

    SVB Financial Group (NASDAQ: SIVB) has a Buy rating at the firm, and this top pick among the bank stocks has a price objective of $190 versus a current $170.38 close. The parent of Silicon Valley Bank has a consensus analyst price target of $176.19, and its 52-week range is $77.87 to $176.77.

Top Performing Stocks To Watch Right Now: StoneMor Partners L.P.(STON)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Buy Edwards Lifesciences: Weak Third-Quarter Performance Is Just A Blip On A Long-Term Growth Story

In my previous two series, I had explained why I believe both the TAVR and SAVR segments of Edwards Lifesciences (EW) are capable of becoming long-term growth drivers for the company. Since then, the company has seen some drop in share prices, especially in the aftermath of rather weak third-quarter performance.

The company failed to meet EPS expectations in Q3 2017, due to changes in accounting for stock-based compensation expenses. The quarter also saw disruptions in manufacturing activity for its Critical Care products at the companys Puerto Rico and the Dominican Republic facilities, due to natural disasters in the Caribbean and US. A significant number of heart valve procedures in Florida and Houston had to be postponed due to hurricanes, Irma and Harvey. These natural disasters affected Edward LifeSciences topline by around $2.0 million.

It can be seen that the weak performance in Q3 2017 was mainly due to several uncontrollable one-time events. However, investors also seem worried about future expectations of sales moderation for the companys TAVR products. I believe that this is a normal trend for any product line, with growth numbers narrowing with increasing base. Besides, with Edwards LifeSciences continuing to focus on expanding access to these novel heart valve therapies as well as working to expand label for existing therapies, the revenue growth trend will be strong for this company in the coming years.

In this article, I will explain why I continue to recommend Edwards LifeSciences as an investment opportunity in 2017.

Despite gradually normalizing revenue growth expectations, Edwards LifeSciences continues to be confident about its TAVR growth guidance.

Certain companies are associated with certain behaviors, and even a slight deviation may be punished by investors. Edwards LifeSciences has been known to increase its full-year revenue guidance in almost all quarterly earnings. Hence, when the company did not change its revenue guidance in Q3 2017, investors were disappointed.

However, it should be remembered that the company has not even lowered its full-year 2017 revenue guidance, and especially its lofty target of reporting revenue growth close to midpoint in the 20% to 25% (linked above) range as compared to 2016, for its transcatheter aortic valve or TAVR segment.

TAVR procedures, especially those using SAPIEN 3 valve, are witnessing strong demand, across hospitals in the US. Even in newly launched international markets such as Japan and some European markets, TAVR therapies have been increasing preferred over surgical valves, at rates even higher than those seen in more established markets. Japan has mainly been focused more on high-risk severe symptomatic aortic stenosis patients, while there remains much more market to explore in the lower-risk patient segments.


Combined with the addition of new indications and new transcatheter products to the portfolio, Edwards LifeSciences continues to believe in the $5.0 billion (linked above) worth market potential for its TAVR segment by year 2021. This implies that the company anticipates around 20% annual growth for its TAVR portfolio, despite FDA approval for Medtronic in the intermediate-risk symptomatic severe aortic stenosis indication. The long-term TAVR revenue guidance also considers future competitive threats, and thus presents a pretty alluring picture in the highly competitive medical technology segment.

Edwards Lifesciences expects to launch SAPIEN 3 Ultra System and CENTERA system by end of 2017.

Edwards Lifesciences has been working on the SAPIEN 3 Ultra system, a transcatheter valve that comes with taller outer skirt, is expected to simplify heart procedures, while reducing time as well as possibility of complications. The company plans to launch this system in Europe by end of 2017 and in the US by late 2018 (linked above). Further, based on robust six month clinical data, the company also plans to launch self-expanding valve system, CENTERA, in Europe by end of 2017 (linked above).

Beyond these late-stage pipeline candidates, Edwards is also exploring safety and efficacy of its best-in-class, SAPIEN 3 transcatheter valve, in low risk patients with aortic stenosis, in ongoing PARTNER III trial. The company is also studying use of transcatheter therapies in patients with Asymptomatic Severe Aortic Stenosis in EARLY TAVR trial.

These next-generation valve programs are expected to further consolidate Edwards LifeSciences position as a leading provider of transcatheter therapies in the world. Besides revenues, increasing adoption of transcather therapies is also expected to boost Edwards Lifesciences margins due to improving product mix.

Going beyond aortic valve replacement, Edwards Lifesciences is also exploring growth avenues for its transcatheter therapies in other structural heart segments such as mitral and tricuspid disease areas. While there is not much sales impact anticipated from these novel technologies in 2018, they nevertheless remain a major mid- to long-term growth driver for the company.

Added to Edwards Lifesciences portfolio through acquisition of Valtech cardio Ltd, announced in late 2016, Cardioband Reconstruction System is being further studied as a transcatheter repair system for the hearts mitral valve and tricuspid valve.

Cardioband has already received a CE Mark in Europe for annular reduction and mitral valve repair in patients suffering with functional mitral regurgitation. A small 31-patient study had confirmed feasibility of transcatheter annuloplasty in FMR patients and had highlighted comparable safety, improved success in implantation rates, and better clinical outcomes as compared to other transcatheter mitral procedures. While the company is enrolling test patients in the ACTIVE trial for testing Cardioband for mitral repair, the system has already earned $1.0 million worth sales in Europe. Cardioband system is expected to emerge as a first-line therapy for mitral disease patients.

Besides, Edwards Lifesciences is also studying the PASCAL Transcatheter Mitral Valve Repair system in CE MARK trial, CLASP. This coupled with Edwards CardiAQ mitral valve replacement system can prove to be significant extensions to the companys transcatheter therapy portfolio in future years.

Finally, based on clinical data and commercial strategy, Edwards Lifesciences will decide on exercising the option to acquire the minimally invasive Harpoon Medical chordal repair system.

INTUITY surgical heart valve may start seeing some traction in late 2017.

While Edwards Lifesciences continues to forecast underlying sales growth in the range of 3% to 4% (linked above) for its surgical valves segment, it is mostly driven by increasing demand for its INTUITY Elite valve system in the US and demand for surgical valves in international markets. The surgical valve market in the US and Europe has been witnessing rapid shift of patients to SAPIEN 3 transcatheter aortic valve system.

INTUITY valve has been approved for add-on payment under the Medicare program starting October 01, 2017. This may help hospitals opt for these valves, since the Medicare program may help reduce their expenses while deploying these rapid-deployment valves for complicated and minimally invasive surgical procedures.

Edwards Lifesciences has also launched INSPIRIS RESILIA aortic valve in Europe, and will allow for valve-in-valve procedures. The company expects to continue with the launch of this valve in the US and European markets in 2018. This technology is mainly targeted towards active and younger patients, who want to move away from mechanical valves due to complications and risks of blood thinners.

HemoSphere will emerge as a potent tool for monitoring hemodynamic status of patients.

Despite multiple setbacks in its Critical Care business, Edwards LifeSciences is confident of reporting 5% to 7% (linked above) underlying growth for this business in 2017. The company is also aggressively moving ahead with the commercial launch of HemoSphere, the companys next-generation hemodynamic monitoring platform. When enhanced with novel surgical recovery capabilities, HemoSphere will be a major differentiating factor and a long-term growth driver for Edwards LifeSciences.

Certain company-specific risks cannot be ignored by investors.

While risks such as increased regulatory oversight and foreign exchange headwinds affect many global medical technology providers, there are certain risks very specific to structural heart disease playerEdwards Lifesciences.

It is no secret that the company depends extensively on the success of its TAVR therapies, as patients and physicians have been actively shifting away from surgical options. However, this segment is expected to face some tough competition from other transcatheter aortic valve players such as Boston Scientific (BSX) and Medtronic (MDT). Edwards Lifesciences did not revise up its full year 2017 revenue growth estimate, despite exceptional performance in first three quarters of 2017. Hence, it has been inferred that the sequential growth in TAVR segment revenues will be much lower, close to 16% (linked above) in Q4 2017.

This growth number seems especially small, considering that in 2016, TAVR penetration in high-risk severe symptomatic aortic stenosis was only 20%. Further, despite approval in intermediate-risk indication, Edwards Lifesciences has already got any major headwind from this label expansion. This has put a dampener on the investor sentiment for the company in late 2017.

Edwards Lifesciences novel Cardioband system which is being developed for mitral valve repair, is also facing competition from peers working on transapical mitral valve replacement technologies.

Then, Edwards Lifesciences has also projected tougher foreign exchange headwinds for Q4 2017, which may have an impact on the companys full year 2017 margins.

All these risks, and especially lower-than-anticipated revenue and margin performance in Q3 2017, has cast a dark shadow on Edwards share prices.

However, I believe that the recent sell-off is not completely justified.

Wall Street analysts have pegged 12-month target for Edwards Lifesciences at $129.42, which will be return on current share prices of about 24.6%. Based on its strong fundamentals, I believe that the company will easily reach these price levels. The recent dip in share prices is more of a knee-jerk reaction and hence, investors should consider this period to be a good entry point for picking up the companys stock.

With multiple positive drivers and strong commercial strategy, the company is bound to make a comeback in 2018. Hence, I recommend investors to consider investing in Edwards LifeSciences in 2017.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.Tagged: Investing Ideas, Long Ideas, Healthcare, Medical Appliances & EquipmentWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here

cheap stock trading

Martin Shkreli, the pharmaceutical industry entrepreneur whod been indicted on charges of securities fraud, had his Twitter account suspended Sunday after he recently harasseda female journalist online.

Lauren Duca, a freelance journalist whose work has appeared in Teen Vogue and other publications, tweeted Thursday a screenshot of a direct Twitter message from Shkreli, in which he invited Duca to be his date to President-elect Trump’s inauguration.

I would rather eat my organs, she tweeted, along with a screenshot of the note.

I would rather eat my own organs pic.twitter.com/IgeCRZqk8w

— Lauren Duca (@laurenduca) January 5, 2017

Shkreli continued to tweet about Duca. He posted several photos of Duca on his Twitter banner and used a doctored photo, showing Duca sitting on a sofa, as his Twitter profile image. He also wrote on his Twitter bio that he had a small crush on Duca and hopes that she doesnt find out. His messages about Duca prompted some of his followers to tweet other doctored photos of Shkreli and Duca.

cheap stock trading: Royal Dutch Shell PLC(RDS.A)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Global oil prices nudged higher Monday even amid reports that Royal Dutch Shell (RDS.A) is re-starting a key Houston refinery that was shuttered by Hurricane Harvey three weeks ago.

  • [By Dustin Parrett]

    Big Oil stocks are the seven “oil supermajors” that do everything from oil drilling to refining to retail sales. This is a list of the Big Oil companies:

    Big Oil CompanyShare PriceYTDMarket CapExxon Mobil Corp. (NYSE: XOM)$83.44-7.58%$353.13BChevron Co. (NYSE: CVX)$113.56-3.5%$217.62BConocoPhillips Co. (NYSE: COP)$48.21-3.78%$61.42BRoyal Dutch Shell Plc. (NYSE ADR: RDS.A)$52.35-3.82%$221.08BBP Plc. (NYSE ADR: BP)$34.12-8.71%$112.69BTotal SA (NYSE: TOT)$50.26-1.35%$124.6BEni SpA (NYSE: E)$31.51-2.3%$58.69B

    Despite being huge global oil companies, shares of Big Oil stocks are all in the red this year. Those losses have all happened even as the Dow is smashing record highs and trading up 6.4% year to date.

  • [By WWW.THESTREET.COM]

    A number of oil and gas companies have backed the accord as well, including Chevron (CVX) , Royal Dutch Shell (RDS.A) and BP (BP) . Exxon (XOM) in March sent a letter to the White House urging it to stay in the Paris agreement, and CEO Darren Woods penned a personal letter to the president addressing the matter, the Financial Times reported last week.

  • [By Dustin Parrett]

    Specifically, the oil supermajors are ExxonMobil Corp. (NYSE: XOM), BP Plc. (NYSE: BP), Chevron Corp. (NYSE: CVX), Royal Dutch Shell Plc. (NYSE ADR: RDS.A), Conoco Phillips (NYSE: COP), Eni SpA (NYSE ADR: E), and Total SA (NYSE ADR: TOT).

  • [By Money Morning News Team]

    A $2 trillion valuation makes the company worth more than Chevron Corp. (NYSE:CVX), BP Plc. (NYSE ADR:BP), Exxon Mobil Corp. (NYSE: XOM), and Royal Dutch Shell Plc. (NYSE: RDS.A) – combined.

cheap stock trading: bebe stores, inc.(BEBE)

Advisors’ Opinion:

  • [By Lisa Levin]

    bebe stores, inc. (NASDAQ: BEBE) shares dropped 26 percent to $3.86. bebe stores will reportedly license www.bebe.com domain name, social media accts. and international wholesale agreements to one or more third parties, according to Reuters.

  • [By WWW.THESTREET.COM]

    Just in the past few weeks, Wall Street has seen bankruptcy filings from sporting goods retailer Gander Mountain, RadioShack successor General Wireless Operations, everyday value price department store operator Gordmans Stores (GMAN) and appliances, electronics and furniture retailer HHGregg (HGG) . Last Wednesday, children’s apparel retailer Gymboree cautioned it was running low on cash and may not survive. Sears Holdings Corp. (SHLD) voiced concerns on Tuesday about its ability to stay in business, while women’s apparel chain Bebe (BEBE) is reportedly on the brink of closing all 170 of its stores.

  • [By WWW.THESTREET.COM]

    Not helping matters was a continued drumbeat of retail death stories such as Payless possibly closing 500 stores, Bebe (BEBE) on the verge of shuttering 170 stores and Sears Holdings’  (SHLD) CFO spreading #fakenews in a new blog post that the retailer is a “viable” entity. It’s not, especially after the language it slipped in its new annual report on Tuesday. 

cheap stock trading: Inter Parfums, Inc.(IPAR)

Advisors’ Opinion:

  • [By Monica Gerson]

    Inter Parfums, Inc. (NASDAQ: IPAR) is estimated to post its quarterly earnings at $0.31 per share on revenue of $110.58 million.

    Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.

cheap stock trading: Archrock, Inc.(AROC)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Company Name

    Share PriceYTDMarket CapClayton Williams Energy Inc. (NYSE: CWEI)$138.8216.4%2.4BDiamondback Energy Inc. (Nasdaq: FANG)$106.365.42%$9.38BWestern Gas Partners LP (NYSE: WES)$65.6411.71%$9.67BTesoro Logistics LP (NYSE: TLLP)$59.3416.79%$6.25BResolute Energy Corp. (NYSE: REN)$46.0811.87%$931.13MAntero Midstream Partners LP (NYSE: AM)$34.9813.28%$6.4BExterran Corp. (NYSE: EXTN)$33.9942.22%$1.19BDominion Midstream Partners LP (NYSE: DM)$32.9011.34%$2.6BNextEra Energy Partners LP (NYSE: NEP)$31.1922.12%$1.68BArchrock Inc. (NYSE: AROC)$16.0021.21%$1.12B

    While some of these stocks have performed well, we arent recommending this list of natural gas stocks. Thats because we arent interested in stocks that have already peaked at Money Morning; were interested in the next big winner. And we have one that could surge in 2017

cheap stock trading: Kinross Gold Corporation(KGC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Given revised commodity deck forecasts (particularly for Steel and Gold) and improved Balance Sheet health (Steels, Precious and Industrials Metals) we are upgrading our ratings on several stocks in our coverage. We generally favor companies that have already initiated specific self-help, have low-cost assets and are less exposed to China supply and demand dynamics. In Steels, we have increased our rating from Hold to Buy on Nucor (NUE) and from Sell to Hold on US Steel. We have also upgraded Kinross Gold (KGC) to a Hold on valuation…On higher-than-peer valuations, we reiterate Sell-rated Coeur Mining (CDE), Franco-Nevada (FNV), Goldcorp (GG), Teck Resources (TCK) and highly leveraged AK Steel given preference to issue further equity if possible.

  • [By Monica Gerson]

    Kinross Gold Corporation (USA) (NYSE: KGC) is projected to post a quarterly loss at $0.01 per share on revenue of $808.09 million.

    Crocs, Inc. (NASDAQ: CROX) is expected to report its quarterly earnings at $0.05 per share on revenue of $265.90 million.

  • [By Lee Jackson]

    Kinross Gold Corp. (NYSE: KGC) may be the stock that give investors the most amount of leverage on a gold rebound. Management reduced the company’s annual capital expenditures forecast to $1.45 billion from $1.6 billion, saving $180 million from its cost restructuring initiatives. Cancellation of its upcoming semiannual dividend payment to its shareholders will save $182 million per year. Kinross expects to produce gold at a cost of $1,000 to $1,200 an ounce this year. The Merrill Lynch target is $7.00, and the consensus target is $6.55. The dividend, which soon will be cancelled, has a yield of 2.9%.

  • [By Lisa Levin]

    Friday afternoon, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from Kinross Gold Corporation (USA) (NYSE: KGC) and Yamana Gold Inc. (USA) (NYSE: AUY).

cheap stock trading: CYS Investments, Inc.(CYS)

Advisors’ Opinion:

  • [By Amanda Alix]

    As the spread between short-term and long-terminterest rates began to contract, strangling profits, competition for MBSes also caused prices to rise. Other agency mREITs were nervous, too. CYS Investments (NYSE: CYS  ) noted at the time that QE3 turned the Federal Reserve into the sector’s biggest rival for mortgage bonds, and as spreads began to shrink, so did dividends. By December of last year, Annaly, Armour, and Capstead Mortgage (NYSE: CMO  ) had all trimmed their payouts.

share market today

Donald Trump’s win has done something extraordinary to the financial sector. Just look at this one-month chart for the Financial Select Sector SPDR ETF (XLF):

Banks Love Trump

This is unexpected on two levels.

First, of course, Trump’s very election came as a shock to many. Second, there was no shortage of people saying stocks would tank if the real estate mogul won. Meantime, not only has the market reached new heights since November 9 but financials have gone from one of the worst-performing sectors to one of the best—almost overnight.

Photographer: David Moir/Bloomberg

share market today: Diamond Hill Investment Group Inc.(DHIL)

Advisors’ Opinion:

  • [By Joe Tenebruso]

    Diamond Hill Investment Group (NASDAQ:DHIL) reported first-quarter results on April 26. The investment management company is benefiting from a seemingly relentless bull market despite shifting competitive dynamics within its industry.

share market today: NiSource, Inc(NI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, utilities shares fell by 2.01 percent. Meanwhile, top losers in the sector included Unitil Corporation (NYSE: UTL), down 9 percent, and NiSource Inc. (NYSE: NI), down 5 percent.

share market today: Advantage Lithium Corp. (AVLIF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

share market today: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Finisar Corporation (NASDAQ: FNSR) shares were also up, gaining 18 percent to $16.70 after the company reported upbeat Q3 earnings.

    Equities Trading DOWN

  • [By Lisa Levin]

    Breaking news

    Finisar Corporation (NASDAQ: FNSR) reported in-line earnings for its fourth quarter, but issued a weak forecast for the current quarter.
    Shares of Booz Allen Hamilton Holding Corporation (NYSE: BAH) dropped around 16 percent in pre-market trading as the company reported a DoJ civil and criminal investigation regarding cost accounting and cost charging practices.
    Shares of Celsion Corporation (NASDAQ: CLSN) jumped over 110 percent in pre-market trading after withdrawing stock offering. T
    Shares of Hornbeck Offshore Services, Inc. (NYSE: HOS) surged around 17 percent in pre-market trading after the company reported a $300 million credit facility.

  • [By Dan Caplinger]

    The stock market had a negative tone on Wednesday, although major benchmarks moved in different directions. The Dow Jones Industrials took the biggest hit, falling triple digits as one of its most influential components suffered an earnings-related drop. Relative strength in the Nasdaq Composite showed cross-currents in the overall market, but several individual stocks had substantial declines for the day, andRite Aid (NYSE:RAD), Diana Shipping (NYSE:DSX), and Finisar (NASDAQ:FNSR) were among the worst performers. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

penny stock research

RBC’s Kurt Hallead and Benjamin Owens offer their take on Transocean (RIG) appearance at the RBC Global Energy and Power Conference:

Bloomberg

Our view: Transocvean continues to execute well, with the focus on revenue efficiency bearing fruit over the last several quarters. However, we believeTransocean shares have limited upside until the market gains more confidence in the supply/demand outlook for floating rigs in 2017-18. Currently, fundamentals continue to weaken for floating rigs, and it remains unclear where dayrates and utilization may bottom.

Expects to see 2H16 opportunities in the jackup market:Transocean expects shallow water to be the first area within the offshore market to see increased spending if oil prices remain constructive. The demand for jackups is being driven by independent oil companies and NOCs. The company still expects the deep water rig count to trend lower through at late-2016 or early-2017.

penny stock research: Clean Energy Fuels Corp.(CLNE)

Advisors’ Opinion:

  • [By Jason Hall]

    Natural gas for transportation leader Clean Energy Fuels Corp (NASDAQ:CLNE) has steadily grown and improved the quality of its business and business results over the past several years. Today’s Clean Energy Fuels is leaner, has a stronger balance sheet, and is in a solid position as a market leader in a growth industry.

  • [By Michael Vodicka]

    Clean Energy Fuels Corp. (CLNE) designs, builds and operates natural gas filling stations in the United States. The company supplies compressed natural gas (CNG) and liquefied natural gas (LNG), serving a fleet of 650 customers, more than 32,000 natural-gas vehicles while owning or supplying more than 350 filling stations in 32 states.

  • [By Lisa Levin]

    In trading on Wednesday, energy shares fell by 1.72 percent. Meanwhile, top losers in the sector included Clean Energy Fuels Corp (NASDAQ: CLNE), down 5 percent, and Frontline Ltd. (NYSE: FRO), down 7 percent.

penny stock research: GenMark Diagnostics, Inc.(GNMK)

Advisors’ Opinion:

  • [By Lisa Levin]

    GenMark Diagnostics, Inc (NASDAQ: GNMK) shares shot up 20 percent to $10.54. Cowen & Co. upgraded GenMark Diagnostics from Market Perform to Outperform.

penny stock research: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

penny stock research: ChannelAdvisor Corporation(ECOM )

Advisors’ Opinion:

  • [By Lisa Levin]

    ChannelAdvisor Corp (NASDAQ: ECOM) shares dropped 24 percent to $10.85 following Q4 results. ChannelAdvisor reported Q4 net income of $5.8 million on revenue of $31.8 million.

Top Biotech Stocks For 2018

What happened

Shares ofPuma Biotechnology(NASDAQ:PBYI) are up 44% at 12:12 p.m., having been up as much as 84% today, as investors digest the Food and Drug Administration documentsposted ahead of Wednesday’s advisory committee meeting to review the approvability of Puma’s breast cancer drug neratinib.

So what

Today’s jump wasn’t because of surprisingly good data but rather a relative lack of negative opinions of neratinib by the FDA reviewers.

Puma Biotechnology is trying to get neratinib approved as an extended treatment for breast cancer after the patient has received surgery followed by Herceptin and chemotherapy. The clinical trial showed that adding neratinib to that standard of care decreased the reoccurrence of breast cancer compared to placebo after a year of treatment with neratinib. But the drug causes severe diarrhea in many patients, which leads to patients reducing the dose or stopping the drug altogether.

Good efficacy with poor tolerability has led investors to worry about the approvability of the drug. The company’snegotiatingwith the FDA over which patients to include in the analysis didn’t help, although that issue appears to be mostlyworked out. Today’s review was fairly neutral, with the documents for the advisory committee noting that the efficacy analysis was basically the same using either set of data, “supporting an effect of neratinib” while also pointing out that “the tolerability of neratinib in this patient population is a concern.”

Top Biotech Stocks For 2018: C.H. Robinson Worldwide, Inc.(CHRW)

Advisors’ Opinion:

  • [By Gary Jakacky]

    Only one company convincingly jumped thru all the hoops: C.H. Robinson Worldwide, Inc. (CHRW).

    If only one of the companies in IYT appear to be undervalued, it might give you pause about how brightly the ETF will shine in the very near future.

  • [By Chad Tracy]

    As it's known today, C.H. Robinson (Nasdaq: CHRW) has again changed with the times.

    Unlike transportation industry titans FedEx (NYSE: FDX) or UPS (NYSE: UPS), C.H. Robinson does not own a fleet of trucks that transport goods. Instead, it specializes in logistics. Other companies hire C.H. Robinson to make their transportation services more efficient.

  • [By Lisa Levin]

    Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) were down 4 percent to $71.69. UBS downgraded C.H. Robinson Worldwide from Neutral to Sell.

Top Biotech Stocks For 2018: NeuroMetrix Inc.(NURO)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    NeuroMetrix (NURO) makes and markets wearable neuro-stimulation therapeutic devices. Cash per share is $1.37, with the stock selling more than 20% below that.

Top Biotech Stocks For 2018: Euro/Yen(EJ)

Advisors’ Opinion:

  • [By Belinda Cao]

    E-House China Holdings Ltd. (EJ), a real estate brokerage, gained 9.2 percent to $9.70, extending it advance to a third week. Its American depositary receipts retreated 3.1 percent Sept. 20 from the highest level since May 2011.